Alan Tan· @alantanmd · X·· 23 hours agoScore70
Body · original
@tompowles1 presented VOLGA at #ESMO26: perioperative durvalumab + neoadjuvant EV vs control in cisplatin-ineligible MIBC
▪️ EFS HR 0.51, p<0.0001
▪️ OS HR 0.58, p=0.0027
▪️ pCR 45% vs 10%
@apolo_andrea @PGrivasMDPhD @shilpaonc @montypal Niklas Klümper #BladderCancer
130 views · 2 likes · 2 reposts · 0 replies
Conference abstracts
LBA2matched by Presidential Symposium I
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgSource: Alan Tan · x.com